2. Signaling Pathways
  3. TGF-beta/Smad
  4. TGF-β Receptor

TGF-β Receptor

Transforming growth factor beta receptors

TGF-β Receptor

Related Products

PDF 0.93 MB

TGF-β receptors (Transforming growth factor-β receptors) are single pass serine/threonine kinase receptors. Transforming growth factor beta (TGF-beta) is a member of a large family of pleiotropic cytokines that are involved in many biological processes, including growth control, differentiation, migration, cell survival, adhesion, and specification of developmental fate, in both normal and diseased states. TGF-beta superfamily members signal through a receptor complex comprising a type II and type I receptor, both serine/threonine kinases.

The type I receptors, referred to as activin receptor-like kinases (ALK), lie at the epicenter of the signaling cascade as they transduce TGF-beta signals to intracellular regulators of transcription known as Smad proteins. ALKs possess an extracellular binding domain, a transmembrane domain, a GS domain that serves as the site of activation by type II receptors, and a kinase domain that activates downstream signaling molecules. ALKs mediate the effect of TGF-beta superfamily on a variety of cellular processes such as proliferation, differentiation, apoptosis, adhesion and migration, and therefore play important roles in many biological processes. Some ALKs have been implicated in several disorders, including tumorigenesis and immune diseases, suggesting that these receptors can be used as drug targets.

TGF-β Receptor Isoform Specific Products:

TGF-β Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P3970C
    KQFK
    		Control
    KQFK is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β.
    KQFK
  • HY-151270
    ALK5-IN-25
    		Inhibitor
    ALK5-IN-25 (compound EX-02) is a potent ALK-5 inhibitor with an IC50 ≤10 nM.ALK5-IN-25 also inhibits ALK-2 (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer.
    ALK5-IN-25
  • HY-P990327
    Anti-ACVR2B Antibody
    		Inhibitor
    The Anti-ACVR2B Antibody is a human antibody expressed in CHO cells, targeting ACVR2B. The Anti-ACVR2B Antibody has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 144.42 kDa. The isotype control for the Anti-ACVR2B Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-ACVR2B Antibody
  • HY-155705
    BMP agonist 1
    		Agonist
    BMP agonist 1 (compound 2 b) is a small-molecule agonist of bone morphogenic protein (BMP). BMP induces C2C12 cell differentiation with BMP and highly depends on active BMP signaling. BMP agonist 1 inhibits GSK3β, increases β-catenin signaling and synergistically regulates Id2and Id3 expression. BMP agonist 1 is used in diseases and defects of the skeleton research.
    BMP agonist 1
  • HY-167864
    M4K2308
    		Inhibitor
    M4K2308 is a selective ether-linked inhibitor of ALK2 with an IC50 of 2 nM. M4K2308 exhibits exceptional selectivity for ALK2 over ALK5 (IC50 of 224 nM). M4K2308 has the potential for the study of diffuse intrinsic pontine glioma (DIPG) research.
    M4K2308
  • HY-148246
    MU1700
    		Inhibitor
    MU1700 is an orally active and potent ALK1/2 inhibitor with IC50s of 13 nM and 6 nM, respectively. MU1700 shows cell membrane permeability and high brain permeability.
    MU1700
  • HY-161398
    TGFβRII-IN-3
    		Degrader
    TGFβRII-IN-3 (Compound 2r) is a selective inhibitor of the TGFβ type II receptor (TGFβ RII) (IC50 = 4.1 μM). TGFβRII-IN-3 inhibits TGFβ signaling by promoting the proteolytic degradation of TGFβ RII. TGFβRII-IN-3 can block endothelial-to-mesenchymal transition and cell migration. TGFβRII-IN-3 can be used in cancer research.
    TGFβRII-IN-3
  • HY-151273
    ALK5-IN-27
    		Inhibitor
    ALK5-IN-27 (Compound EX-04) is a potent ALK-5 inhibitor with an IC50 ≤10 nM. ALK5-IN-27 also inhibits ALK-2 (selectivity ALK2/ALK5 ≤10).
    ALK5-IN-27
  • HY-19628A
    OD36 hydrochloride
    		Inhibitor
    OD36hydrochloride is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with KDs of 37 nM.
    OD36 hydrochloride
  • HY-121025
    BUR1
    		Inhibitor 99.65%
    BUR1 is a BMP upregulator (EC50: 98 nM) and activates BMPRII signalling. BUR1 induces BMP2 and PTGS2 expression. BUR1 reversed pulmonary arterial pressure in Monocrotaline (HY-N0750) induced rats.
    BUR1
  • HY-N4019
    Maohuoside A
    		98.94%
    Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways.
    Maohuoside A
  • HY-145855
    J-1063
    		Inhibitor
    J-1063 is a potent, selective and orally active ALK5 inhibitor with an IC50 of 0.039 µM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis.
    J-1063
  • HY-155939
    M4K2163 dihydrochloride
    		Inhibitor 98.30%
    M4K2163 dihydrochloride is a potent, selective, blood-brain barrier (BBB) permeable activin receptor-like kinase-2 (ALK2) inhibitor, with an IC50 of 19 nM. M4K2163 dihydrochloride can be used in the research of diffuse intrinsic pontine glioma (DIPG).
    M4K2163 dihydrochloride
  • HY-139636
    MCA17-1
    		Inhibitor
    MCA17-1 shows stronger bioactivity than the positive control obeticholic acid (OCA) against liver fibrosis.
    MCA17-1
  • HY-151275
    ALK5-IN-28
    		Inhibitor
    ALK5-IN-28 (compound Ex-05) is a selective ALK-5 inhibitor (IC50≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit growth of tumour in vivo. ALK5-IN-28 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis.
    ALK5-IN-28
  • HY-170964
    HPH-15
    		Inhibitor
    HPH-15 is an anti-migration compound that inhibits cell migration by binding to hnRNP U or suppressing TGF-β signaling. In addition, HPH-15 can also inhibit epithelial-mesenchymal transition (EMT). HPH-15 holds promise for research in the fields of anti-tumor metastasis and anti-fibrosis.
    HPH-15
  • HY-RS14446
    TGFBR1 Rat Pre-designed siRNA Set A
    		Inhibitor

    TGFBR1 Rat Pre-designed siRNA Set A contains three designed siRNAs for TGFBR1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    TGFBR1 Rat Pre-designed siRNA Set A
    TGFBR1 Rat Pre-designed siRNA Set A
  • HY-P99841
    Dalutrafusp alfa
    		Inhibitor
    Dalutrafusp alfa (AGEN-1423; GS-1423) is a specific bifunctional antibody against CD73 and TGF-β, which is involved in the immunosuppressive pathway.
    Dalutrafusp alfa
  • HY-151282
    ALK5-IN-32
    		Inhibitor
    ALK5-IN-32 (compound EX-09) is a selective ALK-5 inhibitor (10 nM<IC50<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis.
    ALK5-IN-32
  • HY-161377
    M4K2306
    		Inhibitor
    M4K2306 is a selective inhibitor for activin receptor-like kinase-2 (ALK2) with an IC50 of 7 nM. M4K2306 is blood brain permeable with a brain to plasma ratio of 75.6.
    M4K2306
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
TGF-β Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.